Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 8/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5158712 | 0.94 | MEN1 (0.39) | TACR1KDM4ESIGMAR1MEN1KMT2A | |
| SCHEMBL5161941 | 0.92 | CCNT1 (0.38) | TACR1KDM4ECCNT1CDK9SIGMAR1 | |
| SCHEMBL5159606 | 0.91 | CCNT1 (0.37) | TACR1KDM4ECCNT1CDK9SIGMAR1 | |
| SCHEMBL5177649 | 0.91 | SIGMAR1 (0.38) | TACR1KDM4ECCNT1CDK9SIGMAR1 | |
| SCHEMBL5159147 | 0.91 | TACR1 (0.38) | TACR1KDM4ECCNT1CDK9SIGMAR1 | |
| SCHEMBL5161746 | 0.91 | CCNT1 (0.39) | TACR1KDM4ECCNT1CDK9SIGMAR1 | |
| SCHEMBL5159324 | 0.90 | CCNT1 (0.39) | TACR1KDM4ECCNT1CDK9SIGMAR1 | |
| SCHEMBL5158058 | 0.89 | SIGMAR1 (0.37) | TACR1KDM4ECCNT1CDK9SIGMAR1 | |
| SCHEMBL5156409 | 0.89 | KDM4E (0.38) | TACR1KDM4ECCNT1CDK9SIGMAR1 | |
| SCHEMBL5158051 | 0.89 | SIGMAR1 (0.37) | TACR1KDM4ECCNT1CDK9SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | TACR1 2/4885KDM4E 2227/4885CCNT1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.